Ophthalmic Eye Dropper Market Size, Share & Trends Analysis Report By Type (Unidose, Preserved, Preservative-free), By Drug Type (Prescription drugs, OTC drugs), By Treatment Type (Glaucoma, Allergies), By Region, And Segment Forecasts, 2024 - 2030
Ophthalmic Eye Dropper Market Growth & Trends
The global ophthalmic eye dropper market size is anticipated to reach USD 20.02 billion by 2030, expanding at a CAGR of 6.01% from 2024 to 2030 according to a new study by Grand View Research, Inc. The rising prevalence of eye disorders such as glaucoma, age-related macular degeneration, and eye syndrome among the aging population worldwide has surged the demand for efficient treatments delivered through eye droppers. Moreover, advancements in drug delivery technologies and the introduction of preservative-free eye drops have notably improved patient adherence to treatment regimens. For instance, preservative-free drops are considered safer and preferred by individuals with dry eyes, thus allowing more frequent use.
The rise in eye conditions such as cataracts, glaucoma, dry eye syndrome, and allergies has significantly bolstered the demand for ophthalmic eye drops. For instance, as reported by the National Glaucoma Research, over 3 million Americans live with glaucoma, out of which 2.7 million are affected by the prevalent open-angle glaucoma among those aged 40 and older. This surge in prevalence aligns with the aging global population, contributing to the increasing occurrence of these conditions. Consequently, there's a pressing necessity for effective treatments like eye drops to address these escalating eye health challenges.
The increased awareness about maintaining optimal eye health and regular eye check-ups has improved the demand for ophthalmic eye drops. This proactive approach helps treat ophthalmic issues quicker which allows eye care providers and eye drops manufacturing companies to assist. For instance, companies like Alcon and Bausch + Lomb have made special eye drops for different eye problems, thereby fueling the market growth.
Ophthalmic Eye Dropper Market Report Highlights
- In 2023, the preserved multi-dose eye dropper type segment accounted for the largest revenue share due to the rising prevalence of ophthalmic diseases and eye infections, coupled with the increased demand for convenient and cost-effective eye drop solutions
- Based on drug type, the prescription drugs segment has always accounted for the largest revenue share in 2023, due to the high prevalence of eye disorders requiring prescription-based treatments, driving the demand for specific medications delivered through eye droppers
- Based on treatment type, the dry eye segment accounted for the largest revenue share in 2023, due to rising prevalence of dry eye syndrome globally, inspiring a higher demand for specialized treatments delivered through eye droppers catering to the eye condition
- North America held the largest share of the market in 2023 due to technological advancements and increasing prevalence of eye disorders, coupled with a growing aging population in the region
- Market players adopt several strategic initiatives to increase the product reach and improve availability in diverse geographic areas
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.1.1. Type
- 1.1.2. Drug Type
- 1.1.3. Treatment
- 1.1.4. Regional scope
- 1.1.5. Estimates and forecast timeline
- 1.2. Research Methodology
- 1.3. Information Procurement
- 1.3.1. Purchased database.
- 1.3.2. GVR’s internal database
- 1.3.3. Secondary sources
- 1.3.4. Primary research
- 1.3.5. Details of primary research
- 1.3.5.1. Data for Primary Interviews in North America
- 1.3.5.2. Data for Primary Interviews in Europe
- 1.3.5.3. Data for Primary Interviews in Asia Pacific
- 1.3.5.4. Data for Primary Interviews in Latin America
- 1.3.5.5. Data for Primary Interviews in MEA
- 1.4. Information or Data Analysis
- 1.4.1. Data analysis models
- 1.5. Market Formulation & Validation
- 1.6. Model Details
- 1.6.1. Commodity flow analysis (Model 1)
- 1.6.1.1. Approach 1: Commodity flow approach
- 1.6.2. Volume price analysis (Model 2)
- 1.6.2.1. Approach 2: Volume price analysis
- 1.7. List of Secondary Sources
- 1.8. List of Primary Sources
- 1.9. Objectives
- Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Type outlook
- 2.2.2. Drug Type
- 2.2.3. Treatment Type
- 2.2.4. Regional outlook
- 2.3. Competitive Insights
- Chapter 3. Ophthalmic Eye Dropper Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook.
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.1.1. Increasing prevalence of eye disorders
- 3.2.1.2. Technological advancements in drug delivery systems
- 3.2.1.3. Aging population and lifestyle changes
- 3.2.2. Market Restraint Analysis
- 3.2.2.1. Limited patient compliance
- 3.3. Ophthalmic Eye Dropper Market Analysis Tools
- 3.3.1. Industry Analysis - Porter’s
- 3.3.1.1. Supplier power
- 3.3.1.2. Buyer power
- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrant
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Technological landscape
- 3.3.2.3. Economic landscape
- Chapter 4. Ophthalmic Eye Dropper Market: Type Estimates & Trend Analysis
- 4.1. Definitions and Scope
- 4.1.1. Unidose eye droppers
- 4.1.2. Preserved multi-dose eye droppers
- 4.1.3. Preservative-free multi-dose eye droppers
- 4.2. Type Market Share, 2018 & 2030
- 4.3. Segment Dashboard
- 4.4. Global Ophthalmic Eye Dropper Market by Type Outlook
- 4.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 4.5.1. Unidose eye droppers
- 4.5.1.1. Unidose eye Droppers Market Estimates and Forecast 2018 to 2030 (USD Million)
- 4.5.2. Preserved multi-dose eye droppers
- 4.5.2.1. Preserved multi-dose eye droppers market estimates and forecast 2018 to 2030 (USD Million)
- 4.5.3. Preservative-free multi-dose eye droppers
- 4.5.3.1. Preservative-free multi-dose eye Droppers Market Estimates and forecast 2018 to 2030 (USD Million)
- Chapter 5. Ophthalmic Eye Dropper Market: Drug Type Estimates & Trend Analysis
- 5.1. Definitions and Scope
- 5.1.1. Prescription drugs
- 5.1.2. OTC drugs
- 5.2. Drug Type Market Share, 2018 & 2030
- 5.3. Segment Dashboard
- 5.4. Global Ophthalmic Eye Dropper Market by Drug Type Outlook
- 5.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 5.5.1. Prescription drugs
- 5.5.1.1. Prescription drugs market estimates and forecast 2018 to 2030 (USD Million)
- 5.5.2. OTC drugs
- 5.5.2.1. OTC drugs market estimates and forecast 2018 to 2030 (USD Million)
- Chapter 6. Ophthalmic Eye Dropper Market: Treatment Type Estimates & Trend Analysis
- 6.1. Definitions and Scope
- 6.1.1. Dry Eye
- 6.1.2. Glaucoma
- 6.1.3. Allergies
- 6.1.4. Conjunctivitis
- 6.1.5. Others
- 6.2. Treatment Type Market Share, 2018 & 2030
- 6.3. Segment Dashboard
- 6.4. Global Ophthalmic Eye Dropper Market by Treatment Type Outlook
- 6.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 6.5.1. Dry Eye
- 6.5.1.1. Dry eye market estimates and forecast 2018 to 2030 (USD Million)
- 6.5.2. Glaucoma
- 6.5.2.1. Glaucoma market estimates and forecast 2018 to 2030 (USD Million)
- 6.5.3. Allergies
- 6.5.3.1. Allergies market estimates and forecast 2018 to 2030 (USD Million)
- 6.5.4. Conjunctivitis
- 6.5.4.1. Conjunctivitis market estimates and forecast 2018 to 2030 (USD Million)
- 6.5.5. Others
- 6.5.5.1. Others market estimates and forecast 2018 to 2030 (USD Million)
- Chapter 7. Ophthalmic Eye Dropper Market: Regional Estimates & Trend Analysis
- 7.1. Regional Market Share Analysis, 2023 & 2030
- 7.2. Regional Market Dashboard
- 7.3. Global Regional Market Snapshot
- 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
- 7.5. North America
- 7.5.1. U.S.
- 7.5.1.1. Key country dynamics
- 7.5.1.2. Competitive scenario
- 7.5.1.3. Regulatory framework
- 7.5.1.4. Reimbursement scenario
- 7.5.1.5. U.S. market estimates and forecast, 2018 - 2030 (USD Million)
- 7.5.2. Canada
- 7.5.2.1. Key country dynamics
- 7.5.2.2. Competitive scenario
- 7.5.2.3. Regulatory framework
- 7.5.2.4. Reimbursement scenario
- 7.5.2.5. Canada market estimates and forecast, 2018 - 2030 (USD Million)
- 7.6. Europe
- 7.6.1. UK
- 7.6.1.1. Key country dynamics
- 7.6.1.2. Competitive scenario
- 7.6.1.3. Regulatory framework
- 7.6.1.4. Reimbursement scenario
- 7.6.1.5. UK market estimates and forecast, 2018 - 2030 (USD Million)
- 7.6.2. Germany
- 7.6.2.1. Key country dynamics
- 7.6.2.2. Competitive scenario
- 7.6.2.3. Regulatory framework
- 7.6.2.4. Reimbursement scenario
- 7.6.2.5. Germany market estimates and forecast, 2018 - 2030 (USD Million)
- 7.6.3. France
- 7.6.3.1. Key country dynamics
- 7.6.3.2. Competitive scenario
- 7.6.3.3. Regulatory framework
- 7.6.3.4. Reimbursement scenario
- 7.6.3.5. France market estimates and forecast, 2018 - 2030 (USD Million)
- 7.6.4. Italy
- 7.6.4.1. Key country dynamics
- 7.6.4.2. Competitive scenario
- 7.6.4.3. Regulatory framework
- 7.6.4.4. Reimbursement scenario
- 7.6.4.5. Italy market estimates and forecast, 2018 - 2030 (USD Million)
- 7.6.5. Spain
- 7.6.5.1. Key country dynamics
- 7.6.5.2. Competitive scenario
- 7.6.5.3. Regulatory framework
- 7.6.5.4. Reimbursement scenario
- 7.6.5.5. Spain market estimates and forecast, 2018 - 2030 (USD Million)
- 7.6.6. Norway
- 7.6.6.1. Key country dynamics
- 7.6.6.2. Competitive scenario
- 7.6.6.3. Regulatory framework
- 7.6.6.4. Reimbursement scenario
- 7.6.6.5. Norway market estimates and forecast, 2018 - 2030 (USD Million)
- 7.6.7. Sweden
- 7.6.7.1. Key country dynamics
- 7.6.7.2. Competitive scenario
- 7.6.7.3. Regulatory framework
- 7.6.7.4. Reimbursement scenario
- 7.6.7.5. Sweden market estimates and forecast, 2018 - 2030 (USD Million)
- 7.6.8. Denmark
- 7.6.8.1. Key country dynamics
- 7.6.8.2. Competitive scenario
- 7.6.8.3. Regulatory framework
- 7.6.8.4. Reimbursement scenario
- 7.6.8.5. Denmark market estimates and forecast, 2018 - 2030 (USD Million)
- 7.7. Asia Pacific
- 7.7.1. Japan
- 7.7.1.1. Key country dynamics
- 7.7.1.2. Competitive scenario
- 7.7.1.3. Regulatory framework
- 7.7.1.4. Reimbursement scenario
- 7.7.1.5. Japan market estimates and forecast, 2018 - 2030 (USD Million)
- 7.7.2. China
- 7.7.2.1. Key country dynamics
- 7.7.2.2. Competitive scenario
- 7.7.2.3. Regulatory framework
- 7.7.2.4. Reimbursement scenario
- 7.7.2.5. China market estimates and forecast, 2018 - 2030 (USD Million)
- 7.7.3. India
- 7.7.3.1. Key country dynamics
- 7.7.3.2. Competitive scenario
- 7.7.3.3. Regulatory framework
- 7.7.3.4. Reimbursement scenario
- 7.7.3.5. India market estimates and forecast, 2018 - 2030 (USD Million)
- 7.7.4. Australia
- 7.7.4.1. Key country dynamics
- 7.7.4.2. Competitive scenario
- 7.7.4.3. Regulatory framework
- 7.7.4.4. Reimbursement scenario
- 7.7.4.5. Australia market estimates and forecast, 2018 - 2030 (USD Million)
- 7.7.5. South Korea
- 7.7.5.1. Key country dynamics
- 7.7.5.2. Competitive scenario
- 7.7.5.3. Regulatory framework
- 7.7.5.4. Reimbursement scenario
- 7.7.5.5. South Korea market estimates and forecast, 2018 - 2030 (USD Million)
- 7.7.6. Thailand
- 7.7.6.1. Key country dynamics
- 7.7.6.2. Competitive scenario
- 7.7.6.3. Regulatory framework
- 7.7.6.4. Reimbursement scenario
- 7.7.6.5. Thailand market estimates and forecast, 2018 - 2030 (USD Million)
- 7.8. Latin America
- 7.8.1. Brazil
- 7.8.1.1. Key country dynamics
- 7.8.1.2. Competitive scenario
- 7.8.1.3. Regulatory framework
- 7.8.1.4. Reimbursement scenario
- 7.8.1.5. Brazil market estimates and forecast, 2018 - 2030 (USD Million)
- 7.8.2. Mexico
- 7.8.2.1. Key country dynamics
- 7.8.2.2. Competitive scenario
- 7.8.2.3. Regulatory framework
- 7.8.2.4. Reimbursement scenario
- 7.8.2.5. Mexico market estimates and forecast, 2018 - 2030 (USD Million)
- 7.8.3. Argentina
- 7.8.3.1. Key country dynamics
- 7.8.3.2. Competitive scenario
- 7.8.3.3. Regulatory framework
- 7.8.3.4. Reimbursement scenario
- 7.8.3.5. Argentina market estimates and forecast, 2018 - 2030 (USD Million)
- 7.9. MEA
- 7.9.1. South Africa
- 7.9.1.1. Key country dynamics
- 7.9.1.2. Competitive scenario
- 7.9.1.3. Regulatory framework
- 7.9.1.4. Reimbursement scenario
- 7.9.1.5. South Africa market estimates and forecast, 2018 - 2030 (USD Million)
- 7.9.2. Saudi Arabia
- 7.9.2.1. Key country dynamics
- 7.9.2.2. Competitive scenario
- 7.9.2.3. Regulatory framework
- 7.9.2.4. Reimbursement scenario
- 7.9.2.5. Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
- 7.9.3. UAE
- 7.9.3.1. Key country dynamics
- 7.9.3.2. Competitive scenario
- 7.9.3.3. Regulatory framework
- 7.9.3.4. Reimbursement scenario
- 7.9.3.5. UAE market estimates and forecast, 2018 - 2030 (USD Million)
- 7.9.4. Kuwait
- 7.9.4.1. Key country dynamics
- 7.9.4.2. Competitive scenario
- 7.9.4.3. Regulatory framework
- 7.9.4.4. Reimbursement scenario
- 7.9.4.5. Kuwait market estimates and forecast, 2018 - 2030 (USD Million)
- Chapter 8. Competitive Landscape
- 8.1. Recent Developments & Impact Analysis, By Key Market Participants
- 8.2. Company/Competition Categorization
- 8.2.1. Innovators
- 8.3. Vendor Landscape
- 8.3.1. List of key distributors and channel partners
- 8.3.2. Key customers
- 8.3.3. Key company market share analysis, 2023
- 8.3.4. AptarGroup, Inc
- 8.3.4.1. Company overview
- 8.3.4.2. Financial performance
- 8.3.4.3. Product benchmarking
- 8.3.4.4. Strategic initiatives
- 8.3.5. Silgan Dispensing Systems
- 8.3.5.1. Company overview
- 8.3.5.2. Financial performance
- 8.3.5.3. Product benchmarking
- 8.3.5.4. Strategic initiatives
- 8.3.6. Alcon plc
- 8.3.6.1. Company overview
- 8.3.6.2. Financial performance
- 8.3.6.3. Product benchmarking
- 8.3.6.4. Strategic initiatives
- 8.3.7. Pfizer
- 8.3.7.1. Company overview
- 8.3.7.2. Financial performance
- 8.3.7.3. Product benchmarking
- 8.3.7.4. Strategic initiatives
- 8.3.8. Bausch & Lomb Incorporated
- 8.3.8.1. Company overview
- 8.3.8.2. Financial performance
- 8.3.8.3. Product benchmarking
- 8.3.8.4. Strategic initiatives
- 8.3.9. Novartis AG
- 8.3.9.1. Company overview
- 8.3.9.2. Financial performance
- 8.3.9.3. Product benchmarking
- 8.3.9.4. Strategic initiatives
- 8.3.10. AbbVie Inc
- 8.3.10.1. Company overview
- 8.3.10.2. Financial performance
- 8.3.10.3. Product benchmarking
- 8.3.10.4. Strategic initiatives
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook